Top

International Journal of Clinical Oncology

Published in:

Open Access 01-08-2017 | Original Article

PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8⁺ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining

Authors: So Yamaki, Hiroaki Yanagimoto, Koji Tsuta, Hironori Ryota, Masanori Kon

Published in: International Journal of Clinical Oncology | Issue 4/2017

Abstract

Background

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. For the development of more effective immunotherapies, it is first necessary to elucidate the immunological escape mechanisms. In this study, we applied our recently developed highly sensitive immunostaining method employing fluorescent phosphor-integrated dot (PID) nanoparticles to evaluate the prevalence of programmed death ligand 1 (PD-L1) in patients with PDAC.

Methods

This study included 42 patients with PDAC who underwent pancreatectomy. We evaluated PD-L1 expression in these patients using PID staining and correlated PD-L1 expression level with each patient’s clinico-pathological features.

Results

PD-L1 expression was detected in 61.9% (26/42) of the patients with PDAC by PID staining. There was a significant difference in overall survival between PD-L1-positive and PD-L1-negative patients [hazard ratio (HR) 2.07, 95% confidence interval (CI) 1.00–4.54; P = 0.049]. Among CD8⁺-tumor-infiltrating lymphocyte-positive cases, the overall survival of PD-L1-positive patients was significantly poorer than that of PD-L1-negative patients (HR 3.84, 95% CI 1.59–10.35; P = 0.003). Univariate and multivariate analyses indicated that PD-L1 expression was an independent predictive poor prognostic factor in patients with PDAC.

Conclusions

PD-L1 expression appears to be an important prognostic factor in patients with PDAC who underwent surgical resection.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29CrossRefPubMed

Wakao F, Nishimoto H, Katanoda K et al (2015) Cancer statistics in Japan 2014. Foundation for Promotion of Cancer Research (FPCR)/National Cancer Center, Tokyo

Winter JM, Cameron JL, Campbell KA et al (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199–1210CrossRefPubMed

Dong H, Zhu G, Tamada K et al (1999) B7-H, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5(12):1365–1369CrossRefPubMed

Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800PubMed

Carter L, Fouser LA, Jussif J et al (2002) PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32(3):634–643CrossRefPubMed

Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulateon of lymphocyte activation. J Exp Med 192(7):1027–1034CrossRefPubMedPubMedCentral

Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454CrossRefPubMedPubMedCentral

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135CrossRefPubMedPubMedCentral

10.

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefPubMed

11.

Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34CrossRefPubMed

12.

Gonda K, Miyashita M, Watanabe M et al (2012) Development of a quantitative method of estrogen receptor expression levels by immunohistochemistry using organic fluorescent material-assembled nanoparticles. Biochem Biophys Res Commun 426(3):409–414CrossRefPubMed

13.

Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2010) International Union against Cancer. TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Chichester, West Sussex/Hoboken

14.

McCarty KS Jr, Miller LS, Cox EB et al (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721PubMed

15.

Herbst RS, Soria JC, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567CrossRefPubMedPubMedCentral

16.

Wang L, Ma Q, Chen X et al (2010) Clinical significance of B7-H1 and B7-1 expressions in pancareatic carcinoma. World J Surg 34(5):1059–1065CrossRefPubMed

17.

Nomi T, Sho M, Akahori T et al (2007) Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13(7):2151–2157CrossRefPubMed

18.

Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):328rv4CrossRefPubMedPubMedCentral

19.

von Bernstorff W, Voss M, Freichel S et al (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7[3 Suppl]:925s–932s

20.

Clark CE, Beatty GL, Vonderheide RH (2009) Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 279(1):1–7CrossRefPubMed

21.

Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465CrossRefPubMedPubMedCentral

Title: PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining
Authors: So Yamaki
Hiroaki Yanagimoto
Koji Tsuta
Hironori Ryota
Masanori Kon
Publication date: 01-08-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1112-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2017

Targeting metabolic reprogramming in KRAS-driven cancers

Inflammation-based prognostic scores as indicators to select candidates for primary site resection followed by multimodal therapy among colorectal cancer patients with multiple metastases

The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis

Targeting DNA repair and replication stress in the treatment of ovarian cancer

Brachytherapy in the treatment of breast cancer

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer